{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-035482","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.165760+00:00","generated_at":"2026-05-25T03:42:36.808707+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Atara Q4 2024 net loss $12.7M; workforce cut 50%; pauses CAR-T programs; EBVALLO BLA resubmission ongoing","bullets":["Net loss of $12.7M ($1.19/share) for Q4 2024 vs $60.5M loss in Q4 2023; full year loss $85.4M.","Cash and equivalents $42.5M at Dec 31, 2024; entered non-binding term sheet for up to $15M equity line with Redmile Group.","Workforce reduced ~50%, retaining ~35 personnel to focus on EBVALLO BLA resubmission and CAR-T wind-down.","Paused ATA3219 and ATA3431 CAR-T programs; discontinued Phase 1 NHL study for ATA3219.","FDA CRL in Jan 2025 cited third-party manufacturing issues; clinical hold on EBVALLO; regulatory update expected in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-035482","json":"https://secwatch.observer/filing/0000950170-25-035482.json","markdown":"https://secwatch.observer/filing/0000950170-25-035482.md","text":"https://secwatch.observer/filing/0000950170-25-035482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/0000950170-25-035482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-20250307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T03:42:36.808707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}